I have included studies done by Mayo Clinic’s Dr. Keith Stewart in the past. Here is a follow-up article, published in Blood, which discusses the history of developing the successful combination of Revlimid, Velcade and dexamethasone (RVD) in treating newly diagnosed multiple myeloma patients:
Union of forces advances myeloma care
A. Keith Stewart MAYO CLINIC
In this issue of Blood, Richardson et al report on a landmarktreatment regimen for newly diagnosed myeloma patients thatfor the first time combines lenalidomide and bortezomib. Thiseffort required a team approach comprising 2 competing pharmaceuticalcompanies (joining forces to study this promising regimen) andmultiple academic medical centers.1
Together, this team conceived of a winning combination chemotherapyregimen using lenalidomide, bortezomib, and dexamethasone (RVD)in newly diagnosed myeloma patients. An unprecedented 100% ofpatients treated at the defined phase 2 dose level respondedto treatment: 74% of patients experienced a 90% reduction intumor burden and 57% entered a complete remission (CR) withina few months of starting treatment. Comparable results havepreviously been reported only after comparatively toxic regimensinvolving intensive rounds of combination chemotherapy and repeateddoses of high-dose melphalan supported by autologous stem celltransplantation.2,3 It is noteworthy that the RVD regimen oftentook more than 4 cycles of therapy to achieve maximal response,with an upgrade in response occurring in 75% of patients whocontinued therapy up to 8 cycles and in half of the patientstreated for more than 8 cycles.
Read the rest by going to: Use of RVD in newly diagnosed multiple myeloma patients.
Feel good and keep smiling! Pat